Page 116 - MBCA_FULL REPORT_FINAL_FOR_WEB

Study Drug(s) Target Biomarkers/ Combination Sponsor
Subtype
2. Evading Growth
Suppressors
Cyclin-Dependent Palbociclib CDK-4/6 All University of Pennsylvania
Kinases
Palbociclib CDK-4/6 All Paclitaxel University of Pennsylvania
Palbociclib CDK-4/6 Hormone+_HER2- Fulvestrant Pfizer
Active, not recruiting Palbociclib CDK-4/7 Hormone+_HER2- Letrozole Pfizer
Active, not recruiting LY2835219 CDK-4/6 All Eli Lilly
LY2835219 CDK-4/6 Hormone+_HER2- Standard Hermone Eli Lilly
Therapy or everoli-
mus/ exemestane
LEE011 CDK-4/6 Hormone+_HER2- Exemestane and Novartis
everolimus
LEE011 CDK-4/6 Hormone+_HER2- Letrozole Novartis
LEE011 and BYL719 CDK-4/6 & PI3 Hormone+_HER2- Letrozole Novartis
SubTotal
3. Inducing Angiogen-
esis
VEGF Signaling Bevacizumab VEGF HER2-
Unknown as of 8/1 Sorafenib VEGF All Capecitabine Yale Cancer Center
Apatanib (YN968D) VEGF All LSK BioPharma
Pazopanib VEGF All Paclitaxel/ carboplatin Rutgers University
4. Resisting Cell Death
IAP (Inhibit apoptosis LCL161 IAP All Paclitaxel Novartis
proteins)
5. Enabling Replica- NOT IN TRIALS FOR
tive Immorality MBC
6. Genome Instability
and Mutation
PARP Inhibitors Veliparib PARP BRCA+ Temozolomide vs. AbbVie
carboplatin/ paclitaxel
Veliparib PARP TripleNegative Doxorubicin National Cancer Institute/
Montiforie Medical Center
Veliparib PARP All Paclitaxel/paraplatin National Cancer Institute/
chemotherapy University of Pittsburgh
Active, not recruiting Veliparib PARP BRCA+ With/without carbo- National Cancer Institute
platin
Veliparib PARP HER2- Paclitaxel/paraplatin National Cancer Institute/
chemotherapy University of Pittsburgh
Veliparib PARP Hormone+_HER2- Carboplatin National Cancer Institute
Active, not recruiting Veliparib PARP BRCA+ AbbVie
Veliparib PARP All Radiation University of Michigan Com-
prehensive Cancer Center
Active, not recruiting Veliparib/cyclophospha- PARP BRCA+ With/without doxo- National Cancer Institute
mide rubicin
BMN 673 "PARP BRCA+ Various Chemo BioMarin
agents
" BRCA+ Various chem- BioMarin BioMarin
otherapeutic
agents
BMN 673 "PARP BRCA+ NCI
AZD2281 (Olaparib) PARP BRCA+ Carboplatin NCI
" BRCA+ BioMarin With/without NCI
Carboplatin